The other candidates were left out either because of their undruggability (e.g. RPA1, ATRX), or because of already existing evidence for their performance as sensitization targets in GBM (PARP1 and MRN complex) [36–38, 42, 43]. The gene discussed is ATRX; the disease is glioblastoma.